On March 12, 2026, a significant step was taken in the fight against epilepsy.
The U.S. Food and Drug Administration (FDA) granted Investigational New Drug (IND) clearance to Unixell Biotech for its innovative cell therapy, UX-GIP001, designed to treat focal epilepsy.
This clearance is a major milestone. It marks UX-GIP001 as the first therapy of its kind—an allogeneic (donor-derived) treatment using induced pluripotent stem cells (iPSCs)—to be approved for clinical study in the United States for epilepsy.
Addressing a Global Need
Epilepsy is a common neurological disorder that affects over 70 million people across the globe. The condition is characterized by seizures driven by neural hyperexcitability. This is often caused by impaired GABAergic interneurons, which are responsible for calming the brain’s electrical activity.
While some treatments exist, many patients continue to suffer from drug-resistant seizures, creating an urgent need for new therapeutic approaches.
How UX-GIP001 Works
Unixell Biotech’s therapy directly targets the root cause of the seizures. The treatment, UX-GIP001, consists of inhibitory neural progenitor cells that are created from iPSCs through a specialized, directed differentiation process.
Once transplanted, these cells are designed to reconstruct the brain’s inhibitory circuits. By restoring the function of these calming neurons, the therapy aims to suppress seizures and restore normal brain activity.
| Therapy Fact Sheet | Details |
| Company | Unixell Biotech |
| Product | UX-GIP001 |
| Cell Type | Allogeneic iPSC-Derived Inhibitory Neural Progenitors |
| Target | Focal Epilepsy |
| Status | FDA IND Clearance Granted |
Proven Safety and Next Steps
According to the press release, preclinical studies in animal models have already demonstrated the efficacy and safety of UX-GIP001, supporting its progression to human trials.
With the FDA’s clearance, Unixell Biotech now plans to initiate a Phase 1 clinical study. This trial will evaluate the safety, tolerability, and preliminary efficacy of UX-GIP001 in patients with drug-resistant focal epilepsy.
This development represents a new wave of hope for patients and families affected by epilepsy, offering a potential path toward a more effective and targeted treatment.
This article is based on a press release issued by Unixell Biotech on March 13, 2026.
